Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties

Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles

“…The poly(methacrylic acid and methacrylate) copolymer allows release of load at a specific pH within the gastrointestinal tract. Table 6, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147 reveals a few examples of nanoparticulate systems which improve bioavailability.…”

Improved Oral Bioavailability and Variability Control in Pharmacokinetic Data – Role of Formulations

“…In order to address the issue of low solubility and large oral dose which impeded oral absorption of abiraterone acetate in clinical pharmacology studies, Solymosi et al [5] created amorphous nanoparticles using continuous flow precipitation technology used frequently for such difficult drug substances [6,7]. This creative adaptation of published technologies enabled novel abiraterone acetate formulation that improved dissolution rate along with enhanced solubility [5].…”

Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method

“…In an earlier study we have shown that using a novel, flow chemistry based precipitation method Aprepitant could successfully be formulated with improved, or similar in vitro and in vivo pharmacokinetic characteristics when compared with the marketed, wet milled nanocrystal formulation, Emend Ò [16]. In this work our aim was to develop a nanostructured Sirolimus formulation using the same cost-effective production method to overcome the limitations and drawbacks of the industrial standard nanocrystal technology while delivering the improved pharmacokinetic characteristics.…”